OL

Nazare, Portugal: If you’ve never witnessed big-wave surfing here, you’re sleeping on one of the planet’s most insane spectacles. Waves topping 100 feet, brutal drops, life-or-death stakes even the jet-ski rescuers are straight legends pulling miracles. Credit: MCYDRO (YT)

$RLMD Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications stocktitan.net/news/RLMD/relm…

Boston-based Modulight Biotherapeutics- Can adding light sensors to nerve cells switch off pain, epilepsy, and other disorders? | Science | AAAS science.org/content/articl…

$RLMD urologytimes.com/view/ndv-01-pr…

Super cool technology finance.yahoo.com/news/modulight…

$ENGN Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months - shares up 50%, market cap now ~$450M. $RLMD a way too cheap? Comparison below. Small position. engene.com/detalimogene-d…

$ENGN vs. $RLMD

@doepke_michel $RLMD

$RLMD is still alive. $100M Underwritten Offering of Common Stock and Pre-Funded Warrants - $2.20 per share. Small Position. relmada.com/for-investors/…

@CrocsAnalyst $RLMD

@MSollender how this company had a MC of $2b??🤡

$NMRA halted - new pending - so must be Koastal-1 P3 data..

You're welcome

$TARA TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures 100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients 64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients 80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposures Favorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse events

@MSollender one more from Paragon Therapeutics, second this week

$MRNS should have very little if any residual value. Sometimes odd things happen in these small commercial types (GTHX comes to mind) but the math is ugly. Cash into Q2 and they’re in a hole with the debt here

@MSollender It interesting financial situation, it seems like they are running out of cash at about 2-4 weeks

The silly and ultimately sad story of $anro 🧵. Bottom line up front: this is another AI-inspired dumpster diving company attempting to game the clinical trial process with fancy terminology for post-hoc-ish subgrouping to eek out "efficacy" from failed compounds 1/16

@LTbioinvestor Finally, a clearing event! It will probably take them a month or two to shut down the program, and after that, it’s all cash from there. Q1 25 cash will be around $1.65 so plenty of upside from here

Strategic Alts soon imho $kzr ... back to 1$